Cure8 research brief
This review summarizes how ulcerative colitis trials have been designed recently and flags common weaknesses (small samples, short follow-up, overreliance on Mayo score). Better-designed trials could produce results that matter more to patients.
Researchers, clinical trial designers, IBD clinicians, and patients on biologics or small-molecule therapies
This Frontiers in Immunology scoping review examined trial registries and published trials (2016–2026) to describe how clinical trials for active ulcerative colitis are designed and measured. The authors report that trials have increased since 2019 and that biologics and small-molecule targeted therapies are the dominant interventions.
They highlight common design limitations: small sample sizes, short follow-up, heavy reliance on the Mayo score, and underuse of patient-reported outcomes and newer endoscopic scoring tools.
The paper recommends that future UC trials use larger, longer, and more patient-centered outcome sets (including PROs and modern endoscopic scores) to better assess benefit and prognosis.
Structured-content depth: abstract — the brief is based on the article’s abstract/summary rather than a full results synthesis.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
This review summarises the rapidly changing drug landscape for Crohn’s disease and ulcerative colitis, including newly approved biologics and small molecules and several emerging therapies that may affect future...
